Jacob D. Cohen
CEO at Mangoceuticals Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Mangoceuticals Inc., 3 years.
Chief executive roles
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 100
270.9% a year in revenue
20% of the scoring weight is on file. Figures cover December 2022 – December 2025.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Mangoceuticals Inc. June 17, 202499.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 9, 2025 | Mangoceuticals Inc. | Grant or award | +500,000 | — | — |
| Jun 5, 2025 | Mangoceuticals Inc. | Gift | −200,000 | — | — |
| Jun 5, 2025 | Mangoceuticals Inc. | Gift | +200,000 | — | — |
| Apr 10, 2025 | Mangoceuticals Inc. | Grant or award | +200,000 | — | — |
| Apr 10, 2025 | Mangoceuticals Inc. | Grant or award | +200,000 | — | — |
| Aug 26, 2024 | Mangoceuticals Inc. | Gift | −800,000 | — | — |
| Aug 26, 2024 | Mangoceuticals Inc. | Gift | +800,000 | — | — |
| Jun 3, 2024 | Mangoceuticals Inc. | Grant or award | +800,000 | — | — |
| Apr 10, 2023 | Mangoceuticals Inc. | Open-market purchase | +275,000 | $1.00 | $275,000 |
| Apr 4, 2023 | Mangoceuticals Inc. | Gift | −8,000,000 | — | — |
| Apr 4, 2023 | Mangoceuticals Inc. | Gift | +8,000,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.